Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 1, 2016, Pages

  Nosadini, Margherita ^a,b   Alper, Gulay ^c   Riney, Catherine J ^d   Benson, Leslie A ^e   Mohammad, Shekeeb S ^a   Ramanathan, Sudarshini ^a,f   Nolan, Melinda ^g   Appleton, Richard ^h   Leventer, Richard J ^i,j   Deiva, Kumaran ^k,l,m   Brilot, Fabienne ^a   Gorman, Mark P ^e   Waldman, Amy T ⁿ   Banwell, Brenda ⁿ   Dale, Russell C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF PADOVA   (Italy)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f WESTMEAD HOSPITAL   (Australia)

^g STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^h ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

ⁱ ROYAL CHILDREN'S HOSPITAL   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k BICÊTRE HOSPITAL   (France)

^l INSERM   (France)

^m UNIVERSITÉ PARIS SACLAY   (France)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84975450762     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000188     Document Type: Article

References (29)

1. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica (Devic's syndrome). Handb Clin Neurol 2014;122:581-599.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
3. Wegner C. Recent insights into the pathology of multiple sclerosis and neuromyelitis optica. Clin Neurol Neurosurg 2013;115:S38-S41.
4. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012;18:1480.
5. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-245.
6. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113-115.
7. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1-16.
8. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014;83:142-150.
9. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-1448.
10. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17: 1225-1230.
11. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013;70: 1110-1117.
12. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014;71:324-330.
13. Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008;122:e1039-e1047.
14. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008;71:93-100.
15. Beres SJ, Graves J, Waubant E. Rituximab use in pediatric central demyelinating disease. Pediatr Neurol 2014;51: 114-118.
16. Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm 2014;1:e46. doi: 10.1212/NXI.0000000000000046.
17. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
18. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
19. Dale RC, Tantsis EM, Merheb V, et al. Antibodies toMOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014; 1:e12. doi: 10.1212/NXI.0000000000000012.
20. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76: 1310-1315.
21. Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 2010;3:93-105.
22. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-1277.
23. Kim SM, Park J, Kim SH, et al. Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. PLoS One 2013; 8:e82325.
24. Wang H, Wang K, Zhong X, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol 2012;32:1007-1011.
25. Nakashima I, Takahashi T, Cree BA, et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 2011;18:997-998.
26. Gredler V, Mader S, Schanda K, et al. Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. J Neurol Sci 2013;328:77-82.
27. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072-3080.
28. He D, Yu Y, Yan W, Dai Q, Xu Z, Chu L. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report. Pediatr Neurol 2014;51:255-258.
29. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 2012;18:1022-1026.